| A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib (NCT05204628) | Xuanzhu Biopharmaceutical Co., Ltd. | 2022-02-07 |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NCT05221840) | AstraZeneca | 2022-02-07 |
| A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment (NCT04933695) | Amgen | 2022-01-28 |
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (NCT05098132) | Synthekine | 2022-01-25 |
| Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (NCT04966676) | University Health Network, Toronto | 2022-01-24 |
| A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC (NCT06422546) | Beijing Cancer Prevention & Treatment Society | 2022-01-15 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC (NCT05153408) | Blueprint Medicines Corporation | 2022-01-13 |
| RTX-224 Monotherapy in Patients With Solid Tumors (NCT05219578) | Rubius Therapeutics | 2022-01-12 |
| SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. (NCT05020769) | Sichuan Baili Pharmaceutical Co., Ltd. | 2022-01-06 |
| Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer (NCT05003037) | Li Zhang, MD | 2022-01-06 |
| Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged (NCT05116618) | University of Colorado, Denver | 2022-01-06 |
| Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC (NCT05430386) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2022-01-05 |
| Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (NCT05298176) | Amsterdam UMC, location VUmc | 2022-01-04 |
| Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients (NCT04912687) | Institut Bergonié | 2022-01-01 |
| Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer (NCT05425134) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-01-01 |
| Dose-escalation by Hypofractionated Stereotactic Radiotherapy for Brain Metastases in Non Small Cell Lung Cancer (NCT05588206) | First People's Hospital of Hangzhou | 2022-01-01 |
| Feasibility of a Hybrid Delivery of Home-based Cluster Set Resistance Training in Lung Cancer (NCT05014035) | University of South Carolina | 2022-01-01 |
| Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors (NCT03989050) | University of Cologne | 2022-01-01 |
| Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC (NCT05974007) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-01-01 |
| A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer (NCT05186506) | Sichuan University | 2022-01-01 |
| Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors (NCT05117138) | Beijing Immunochina Medical Science & Technology Co., Ltd. | 2022-01-01 |
| Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation (NCT05460195) | Shanghai Chest Hospital | 2022-01-01 |
| FRAME-001 Personalized Vaccine in NSCLC (NCT04998474) | Frame Pharmaceuticals B.V. | 2022-01-01 |
| Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer (NCT05312840) | People's Hospital of Quzhou | 2022-01-01 |
| Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC (NCT06569420) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2021-12-31 |
| Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies (NCT05054725) | Revolution Medicines, Inc. | 2021-12-30 |
| Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib (NCT04769388) | Beijing Cancer Prevention & Treatment Society | 2021-12-28 |
| Lorlatinib Continuation Study (NCT05144997) | Pfizer | 2021-12-28 |
| Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes (NCT05792995) | Xin-Hua Xu | 2021-12-21 |
| A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer (NCT05138900) | Roswell Park Cancer Institute | 2021-12-16 |
| Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (NCT05013099) | ImaginAb, Inc. | 2021-12-09 |
| Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) (NCT05255406) | Fudan University | 2021-12-09 |
| Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer (NCT05751018) | Peking Union Medical College Hospital | 2021-12-08 |
| SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. (NCT05020457) | Sichuan Baili Pharmaceutical Co., Ltd. | 2021-12-07 |
| A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients (NCT05210946) | The First Affiliated Hospital of Soochow University | 2021-12-06 |
| Anatomical Location and Metastasis Pattern of Intrapulmonary Lymph Nodes in NSCLC (ECTOP-1010) (NCT05094882) | Fudan University | 2021-12-01 |
| Immune and Genomic Markers in ALK+ NSCLC (NCT04881916) | Massachusetts General Hospital | 2021-12-01 |
| DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS (NCT05254119) | Mahmut Gumus | 2021-12-01 |
| Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer. (NCT05102110) | Origin Sciences | 2021-12-01 |
| The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (NCT05167851) | Yonsei University | 2021-12-01 |
| Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer (NCT05170581) | The Second Affiliated Hospital of Shandong First Medical University | 2021-12-01 |
| [18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer. (NCT05157659) | Amsterdam UMC, location VUmc | 2021-12-01 |
| Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer (NCT05034055) | Yonsei University | 2021-12-01 |
| A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (NCT04916002) | Regeneron Pharmaceuticals | 2021-11-30 |
| RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) (NCT05154344) | Intergroupe Francophone de Cancerologie Thoracique | 2021-11-29 |
| Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. (NCT05068427) | Chipscreen Biosciences, Ltd. | 2021-11-23 |
| Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification (NCT05015608) | Hutchison Medipharma Limited | 2021-11-22 |
| RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada (NCT05933044) | AstraZeneca | 2021-11-19 |
| Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) (NCT05559645) | Peking Union Medical College Hospital | 2021-11-18 |
| Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NCT05012254) | Fundación GECP | 2021-11-18 |
| Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT05089734) | Gilead Sciences | 2021-11-17 |
| Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (NCT05024214) | 3D Medicines (Sichuan) Co., Ltd. | 2021-11-15 |
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC (NCT04984811) | NeoImmuneTech | 2021-11-15 |
| ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma (NCT05014464) | Hunan Province Tumor Hospital | 2021-11-13 |
| Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment (NCT04852588) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2021-11-09 |
| A Study of NDI 1150-101 in Patients With Solid Tumors (NCT05128487) | Nimbus Saturn, Inc. | 2021-11-05 |
| A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors (NCT05084859) | Biosplice Therapeutics, Inc. | 2021-11-03 |
| Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer (NCT04808050) | AstraZeneca | 2021-11-03 |
| Milademetan in Advanced/Metastatic Solid Tumors (NCT05012397) | Rain Oncology Inc | 2021-11-01 |
| Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model (NCT05136014) | Central Hospital, Nancy, France | 2021-11-01 |
| First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine (NCT05104515) | Oxford Vacmedix UK Ltd. | 2021-11-01 |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (NCT05005403) | AbbVie | 2021-11-01 |
| Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (NCT05007769) | Washington University School of Medicine | 2021-10-31 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (NCT04981119) | A2 Biotherapeutics Inc. | 2021-10-29 |
| NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NCT04880863) | NeoTX Therapeutics Ltd. | 2021-10-26 |
| Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC (NCT05098990) | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. | 2021-10-25 |
| A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer (NCT05104788) | Peking University Cancer Hospital & Institute | 2021-10-25 |
| Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients (NCT05801107) | Qilu Pharmaceutical Co., Ltd. | 2021-10-25 |
| Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (NCT05061537) | Pfizer | 2021-10-20 |
| Lactobacillus Bifidobacterium V9(Kex02)Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer Patients (NCT05094167) | Jiangxi Provincial Cancer Hospital | 2021-10-19 |
| Supportive Care Mobile Application for Patients With NSCLC (NCT04629300) | Massachusetts General Hospital | 2021-10-15 |
| Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (NCT04911166) | The Methodist Hospital Research Institute | 2021-10-14 |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab (NCT05029882) | AbbVie | 2021-10-13 |
| Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC (NCT04895930) | Shanghai Chest Hospital | 2021-10-12 |
| BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab (NCT04933903) | Brown University | 2021-10-05 |
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (NCT04853017) | Elicio Therapeutics | 2021-10-04 |
| Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer (NCT05059951) | Hunan Province Tumor Hospital | 2021-10-03 |
| TEIPP Immunotherapy in Patients With NSCLC (NCT05898763) | Erasmus Medical Center | 2021-09-29 |
| Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT) (NCT05815472) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-09-28 |
| Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors (NCT04930432) | Betta Pharmaceuticals Co., Ltd. | 2021-09-24 |
| HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors (NCT05124743) | Alaunos Therapeutics | 2021-09-24 |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) (NCT04914897) | Sanofi | 2021-09-23 |
| A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors (NCT05116891) | Cantargia AB | 2021-09-22 |
| Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer (NCT04965818) | Taiho Oncology, Inc. | 2021-09-20 |
| A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer (NCT04982926) | Taiho Oncology, Inc. | 2021-09-16 |
| A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (NCT04765059) | AstraZeneca | 2021-09-12 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804) | OncoResponse, Inc. | 2021-09-09 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (NCT05059444) | Guardant Health, Inc. | 2021-09-07 |
| Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC (NCT05009836) | Hutchison Medipharma Limited | 2021-09-06 |
| Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy (NCT04487457) | University Hospital, Tours | 2021-09-03 |
| Gut Microbiota Reconstruction for NSCLC Immunotherapy (NCT05008861) | Shanghai Zhongshan Hospital | 2021-09-01 |
| Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (NCT04919811) | Nuvation Bio Inc. | 2021-09-01 |
| Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer (NCT04822298) | Amgen | 2021-08-31 |
| Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients (NCT04880382) | Institut Bergonié | 2021-08-27 |
| FL-101 in Surgically Resectable Non-Small Cell Lung Cancer (NCT04758949) | Flame Biosciences | 2021-08-25 |
| Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC (NCT04585490) | Maximilian Diehn | 2021-08-25 |
| Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers (NCT04946968) | National Cancer Centre, Singapore | 2021-08-24 |
| Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC (NCT04943029) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2021-08-20 |
| Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (NCT04881045) | Pfizer | 2021-08-18 |
| Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC (NCT04997382) | Hunan Province Tumor Hospital | 2021-08-17 |